miRNA-23b as a biomarker of culture-positive neonatal sepsis

Ahlam Fatmi  
Laboratory of Applied Molecular Biology and Immunology

Sid Ahmed Rebiahi  
Laboratory of Microbiology

Nafissa Chabni  
Faculty of Medicine Tlemcen University

Hanane Zerrouki  
Laboratory of Microbiology

Hafsa Azzaoui  
Laboratory of Applied Molecular Biology Microbiology

Yamina Elhabiri  
Laboratory of Applied Molecular Biology

Souheila Benmassour  
Neonatal Department Hospital of Tlemcen

José Santiago Ibáñez-Cabellos  
Universitat de Valencia

Mourad Aribi  
Laboratory of Applied Molecular Biology and Microbiology

José Luis García-Giménez  
Universitat de Valencia

Federico V Pallardó  
University of Valencia  federico.v.pallardo@uv.es

Short report

Keywords: early-onset sepsis, haemoculture, late-onset sepsis, miR-23b, newborns

DOI: https://doi.org/10.21203/rs.3.rs-23232/v2

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background: Neonatal sepsis remains an important cause of morbidity and mortality. The ability to quickly and accurately diagnose neonatal sepsis based on clinical assessments and laboratory blood tests remains difficult, where haemoculture is the gold standard for detecting bacterial sepsis in blood culture. It is also very difficult to study because neonatal samples are lacking.

Methods: Forty-eight newborns suspected of sepsis admitted to the Neonatology Department of the Mother-Child Specialized Hospital of Tlemcen. From each newborn, a minimum of 1-2 ml of blood was drawn by standard sterile procedures for blood culture. The miRNA-23b level in haemoculture was evaluated by RT-qPCR.

Results: miR-23b levels increased in premature and full-term newborns in early onset sepsis (p < 0.001 and p < 0.005 respectively), but lowered in late onset sepsis in full-term neonates (p < 0.05) compared to the respective negative controls. miR-23b levels also increased in late sepsis in the negative versus early sepsis negative controls (p < 0.05). miR-23b levels significantly lowered in the newborns who died from both sepsis types (p < 0.0001 and p < 0.05 respectively). In early sepsis, miR-23b and death strongly and negatively correlated (correlation coefficient = -0.96, p = 0.0019). In late sepsis, miRNA-23b and number of survivors (correlation coefficient = 0.70, p = 0.506) positively correlated.

Conclusions: Lowering miR-23b levels is an important factor that favours sepsis development, which would confirm their vital protective role, and strongly suggest that they act as a good marker in molecular diagnosis and patient monitoring.

Introduction

During the neonatal period, the immune system is still immature, and most immune responses are ensured by innate immunity, triggered following intimate contact between immune cells and microbes. In newborns, altered microbiota or microbial deprivation, as well as reduced microbial diversity, greatly increase the risk of immune dysregulation and proneness to inflammatory diseases. This makes neonates very fragile and more sensitive to several infectious diseases [1, 2].

Nowadays, neonatal sepsis is one of the most dangerous conditions to affect newborns during the first 28 days of life, and is a first-order public health system problem given its very high risk of mortality and morbidity [3, 4]. It is frequently divided into two types according to onset time: early-onset sepsis (EOS), when the process develops during the first 72 h of life; late-onset sepsis (LOS), when it occurs after the first 72 h. Unlike to fungi and parasites, bacteria and viruses are the commonest causative agents involved in neonatal sepsis aetiology [5, 6].

Sepsis is commonly diagnosed by microbiological blood culture, but this can take days to perform, can suffer contamination and provide false-negative results. An empirical antibiotic therapy approach in neonatal sepsis is common clinical practice. In the presence of suspected bacterial infection, the use of
random antibiotics is often unnecessary and prolongs the treatment of many uninfected newborns. Increasing the risk of multi-resistant strains emerging, however, or delaying or stopping antibiotic use in septicemic newborns can also be catastrophic given rapid disease progression [7, 8]. In addition, caring for newborns in specific hospital departments is a drain on human and financial resources [9, 10].

MicroRNAs (miRNAs), a class of small single-stranded non-coding regulatory RNAs of about 19 to 22 nucleotides, are involved in a wide range of biological processes and have opened a new window of hope to diagnose, and even treat, various diseases. miRNA binds to specific mRNA molecules to inhibit the expression of target genes or to degrade mRNA, which then contributes to cell proliferation, differentiation, development, metabolism, apoptosis and other physiological activities [11, 12]. Given their role in various cellular processes, recent studies reveal how miRNAs may have the potential to be an early biomarker in a number of diseases, including sepsis [13]. Among microRNAs, we can identify miR-23b. Chromosomal region 9q22.32 produces miR-23b. The combined body of available works suggests that miR-23b expression is not only modulated by a diverse array of stimuli in cells from different lineages, but also participates in multiple gene regulatory feedback loops [14]. Nevertheless, the role of miRNAs in neonatal sepsis has not been widely explored. It is noteworthy that miR-23b is a proven and important regulator of the innate immune response in both cancer and several inflammatory processes [15]. In addition, some studies show that microR-23b expression in the peripheral blood of sepsis patients is related to the manifestation of an inflammatory state and may, therefore, be used to evaluate the severity and prognosis of adults patients with this disease [16]. In another study, miR-23b is proposed as an essential contributor to cardiac fibrosis activation to mediate the development of myocardial dysfunction in late sepsis. This report suggests that blocking miR-23b expression might be an effective approach to prevent sepsis-induced cardiac dysfunction [17]. Another study reveals that miR-23b inhibition down-regulates the expression of programmed death ligand-1 (PD-L1) on splenic T lymphocytes of septic mice. This discovery opens up new therapeutic pathways in late stages of the septic phase [18]. Finally, another study demonstrates that miR-23b is an anti-inflammatory factor that negatively regulates the inflammatory responses induced by lipopolysaccharide (LPS) by targeting metalloproteinase 10 (ADAM10) [19].

Haemocultures are the "gold standard" for identifying bacterial and fungal infections in the bloodstream. However, they are limited by large volume requirements to maximise sensitivity and often imply long incubation times. To address some of these limitations, many advances have been developed to improve sensitivity and to reduce the time required to identify the cause of bloodstream infections. Molecular amplification techniques have been developed to replace the incubation step in blood culture targeting conserved regions of microbial genomes for amplification, such as rRNA genes and interspace region 16S-23S [20–22].

In this study, we attempted to estimate the expression levels of candidate circulating miR-23b in small cohorts of newborns diagnosed with early (EOS) or late (LOS) sepsis by microbiological blood culture test in the Neonatology Department of Mother & Child Specialized Hospital Establishment of Tlemcen (northwest Algeria). We show for the first time that miR-23b can be considered a potential marker of
sepsis in haemocultures from neonate peripheral blood samples. Hence, we demonstrated that miR-23b levels increased in EOS, but lowered in LOS, compared to the respective negative controls. These levels also increased in the LOS negative controls compared to the EOS negative controls. Therefore, the drop in miR-23b levels would undoubtedly be an important factor that favours sepsis development, which would confirm their vital protective role on the one hand, and would strongly suggest their use as a good marker in both molecular diagnosis and patient monitoring on the other hand.

Patients And Methods

Ethical aspects

The present study was approved by the Local Ethics Committee of Tlemcen University. Parents or legal guardians gave written informed consent so that the samples from all the participating infants could be used according to the Declaration of Helsinki.

Study population

Of the 2,561 newborns admitted during a 12-month period to the Neonatology Department of Mother & Child Specialized Hospital Establishment (EHS, Etablissement Hospitalier Spécialisé Mère-Enfant) of Tlemcen (northwest Algeria), 254 (9.91%) newborns with sepsis were recorded. Forty-eight cases aged up to 28 days with clinical features of sepsis (e.g. fever, respiratory distress, bradycardia, tachycardia, convulsions, cyanosis), and an association, or not, with premature rupture of membranes (PROM), and abnormal amniotic liquid as risk factors [23], who met the neonatal sepsis inclusion criteria, were recruited in a prospective cohort study. The exclusion criteria included those patients without sepsis clinical features or those who had received antibiotherapy before sampling. Newborns included 20 females and 28 males. The 48 patients were randomly divided into two groups of 27 EOS, including nine cases of preterm newborns and 21 LOS patients.

Samples for blood haemoculture

Peripheral blood samples (1–2 mL) were inoculated into aerobic bottles containing paediatric haemoculture medium (BIOSCAN, Sétif, Algeria) to be incubated at 37ºC for 4–6 h with agitation. Aliquots of 2 mL were collected and stored at –80°C until RNA extraction.

Total RNA extraction, including miRNA, was performed with a minimum of 200 µL of cell-free supernatant obtained after centrifuging an aliquot at 1200 rpm for 10 min using the miRNeasy Serum/Plasma kit (Qiagen, Valencia, Spain) according to the manufacturer’s protocol. RNA was eluted with 20 µL of RNase-free water and was then quantified in a NanoDrop ND 2000 UV spectrophotometer (Thermo Scientific, Wilmington, DE, USA).

Reverse transcription PCR and Real-time qPCR
Total RNA (1 μL) was converted into complementary DNA (cDNA) by reverse transcriptase using the miRNA TaqMan reverse transcription kit and miRNA-specific stem and loop primers (Part No. 4366597, Applied Biosystems, Inc., CA, USA). Real-time PCR was performed in an Applied BioSystem 7900HT Thermocycler (Applied Biosystems/Thermo Fisher, USA) with 40 cycles. The primers herein used were designed for miRNA-23b (hsa-miR-23b (Assay ID 002126). Thermo Fisher, CA, USA), and U6 snRNA (U6-snRNA (Assay ID 001973). Thermo Fisher, CA, USA), was used for standardisation purposes by the delta-delta CT method ($2^{-ΔΔCT}$).

**Statistical analysis**

The results represent the mean (± standard deviation) of the median values of three independent replicate experiments. Analyses of variance were carried out by Mann Whitney U or Kruskal–Wallis non-parametric tests using GraphPad Prism 8.0.1 (244) as data were not normally distributed [24]. $P$-value < 0.05 was considered statistically significant.

**Results And Discussion**

Forty-eight haemocultures were performed in this study, of which 18.75% were premature and 81.25% at-term. Gender, temperature, heart rate, respiratory rate, glycaemia and caesarean vs. vaginal delivery characteristics were not statistically different between the control and the positive haemoculture groups. However, neonates’ weight in both sepsis types was significantly different to C-reactive protein (CRP), which significantly differed in the EOS neonates. The clinical information of the 48 patients is shown in Table 1.

**Changes in the miRNA-23b expression levels in early onset sepsis**

The miR-23b expression levels in the neonatal sepsis samples were analysed by the quantitative real-time PCR method. Our results showed that, compared to the control group, the miR-23b expression levels significantly differed in the neonatal sepsis samples either in the at-term or premature neonates ($p < 0.001$ KW) (Fig. 1). The miR-23b expression significantly lowered in the neonates who died of sepsis ($p < 0.0001$, $p < 0.05$ at-term and premature infants, respectively), and significantly increased in the neonates who survived with a positive haemoculture ($p < 0.005$, $p < 0.001$). These results reveal that miR-23b expression correlates with sepsis progression.

**Changes in the miR-23b expression levels in late onset sepsis**

Figure 2 shows how the miR-23b expression in LOS significantly lowers in both the dead and surviving newborns with a positive haemoculture, with $p < 0.005$ and $p < 0.05$, respectively, compared to the controls and for all comparisons ($p < 0.05$ KW). Two cases presenting the clinical signs of sepsis died, but the haemoculture was negative. In this case, we recorded a significant drop in the miR-23b level with a negative haemoculture ($p < 0.05$). This case was considered a false-negative haemoculture, probably
due to the sampling time [25] or another limitation, like the presence of unculturable or fastidious microorganisms that could decrease its sensitivity [26].

Change in the miRNA-23b expression levels in newborns in two different stages

The differences between our results when comparing EOS and LOS led us to think back to the starting point before sepsis appeared. Figure 3 shows the miR-23b expression level after the first 72 h of life and beyond that time in the control patients. The results revealed a significant increase in the miR-23b level after 72 h of live performance \( p < 0.05 \) compared to that before the first 72 h of life.

The correlation between miR-23b, sepsis and death during the neonatal period

Figure 4 shows a very strong negative correlation between miR-23b and death in early sepsis patients (\( r = -0.96, p = 0.002 \)), the same for premature, with a negative correlation with miR-23b and death sepsis (\( r = -0.89, p = 0.0001 \)), but the miR-23b level correlated negatively with sepsis (\( r = -0.81, p = 0.39 \)). With late sepsis, a low negative non-significant correlation is observed between miR-23b and the appearance of sepsis (\( r = -0.26, p = 0.32 \)). Nevertheless, we show a positive correlation between miRNA-23b levels in both the control and non-survivor patients (\( r = 0.70, p = 0.506 \)).

Infant and late foetal deaths are key factors when assessing a country’s level of social protection [27, 28]. In neonatal sepsis, the leading treatment is antibiotics, which target the infecting pathogen, but not the inflammatory process that continues to increase. Therefore, an ideal treatment approach should include antimicrobial and anti-inflammatory drugs to neutralise the rising inflammatory cascade and the resulting "cytokine storm" in neonatal sepsis [29]. Newborns immune status during the perinatal period differs from that of adults. Neonatal immune responses are generally directed against the generation of T helper type 1 (Th1)-related proinflammatory immune responses, while favouring the Th2-related anti-inflammatory /immunosuppressive response [30]. This process represents an efficient strategy to address the unique challenges of the neonatal period, including maintaining tolerance to maternal antigens \textit{in utero} and balancing the transition from the sterile intrauterine environment to the antigen-rich outside world [30].

miRNAs are endogenous, non-coding, single-stranded RNAs (~22 nucleotides long) with the ability to degrade mRNA or inhibit translation, which then regulates gene expression at the post-transcriptional level [11]. We know that the expression of \( \geq 30\% \) of human genes is controlled by miRNAs [31]. miRNAs also regulate molecular signalling pathways and immune activities [32]. The invasion of pathogenic microorganisms, followed by rapid miRNAs production, promote the release of inflammatory factors that cause immune hyperactivity, and induce apoptosis or degrading inflammatory factors that can provoke immunosuppression [33, 34].

The biomarkers frequently used in neonatal sepsis are still not completely conclusive. but have shown some potential for \textit{in vitro} diagnoses [35]. Since their discovery, circulating miRNAs in human peripheral serum are used as biomarkers of various cancer types. The use of miRNAs as diagnostic and prognostic markers has extended to other diseases, including sepsis, but their role in infectious diseases has rarely
been studied [36, 37]. One of the main obstacles to establish a well-defined link between miRNAs and sepsis lies in the fact that sepsis can be caused by very different factors that cause similarities and differences, which influence the patient’s situation itself and make sepsis so very complicated [38]. This is why the association of miRNAs with sepsis diagnosis remains controversial [39].

miRNAs from different biological fluids can be used for the early prediction and evaluation of neonatal sepsis, where various miRNAs are down-regulated, and contribute to the initiation of the immune response to infection [40]. To date, no studies are available on miRNAs in both neonatal sepsis types, i.e., EOS and LOS. To the best of our knowledge, no study has investigated miRNAs expression levels in haemocultures from septic patients and their change according to neonatal sepsis types.

The neonatal immune response to sepsis depends on the timing of onset, relative pathogens and developmental age [41], and is markedly different from the immune response in adults because of specific neonatal microbial susceptibility and atopic properties. Differences have been reported in the regulation of target gene expression by miRNAs in innate immunity [32]. A study of ten immune-regulating miRNAs, whose expression significantly altered more than 2-fold in neonates with sepsis compared to uninfected neonates, showed that miRNA expression levels were altered, and that this alteration in miRNAs modulated the immune response during neonatal sepsis so as to repress inflammatory response [40]. In another study [42], low miRNA-26a levels have been correlated with the up-regulation of IL-6 expression in blood mononuclear cells and serum. Nevertheless, neither newborns age nor sepsis type has been specified. There are also reports indicating that miR-15a/16 can be used as a potential biomarker for the diagnosis and prognosis of neonatal sepsis, and that miRNA15a/16 regulation may limit the inflammatory response to LPS [43].

Although the discovery of miR-23b is recent [11, 16], intense research efforts have been made to show that it is involved in various physiological and pathophysiological processes [14]. So, it has been revealed as an essential moderator of several physiological pathways that regulate the differentiation of many cell lines, such as keratinocytes, chondrocytes and skeletal muscle. miR-23b also regulates inflammatory response in several autoimmune diseases through suppressing proinflammatory signalling pathways in resident cells, such as human fibroblast-like synoviocytes, and in primary kidney cells and astrocytes from mice [44]. miR-23b also plays a critical role in certain pathologies, including acute myocardial infarction, inflammatory heart diseases and sepsis-induced cardiac dysfunction [45, 46], diabetic nephropathy [46] and prostate cancer [47]. We herein demonstrate for the first time the presence of miR-23b in haemocultures from neonatal sepsis and their interest for diagnosis and prognosis in early and late sepsis.

In sepsis, miR-23b has been reported to be down-regulated in peripheral blood mononuclear cells (PBMCs) from adult patients and in the LPS-induced THP-1 human monocyctic cell line, and has been negatively correlated with the production of proinflammatory cytokines. Increased miR-23b expression has been shown to induce the down-regulation of proinflammatory cytokines production and LPS-stimulated apoptosis [19].
In the present study, we revealed that at-term birth, the neonates with negative haemocultures (the control group) presented low miR-23b levels during the first 72 h of life, which started to increase after 72 h. Conversely, the neonates with a positive haemoculture who did not survive infection always showed the lowest miR-23b levels, regardless of whether they were premature or born at term. In addition, the neonates with a positive haemoculture who survived infection had high miR-23b levels during the first 72 h of life, irrespectively of whether they were born at term or premature. Thus the increase in miR-23b levels during the first 72 h of life in septic neonates may be a potent prognostic factor for survival and a sensitive clinical marker in both preterm and at-term neonates.

It has been recently shown with an animal model of sepsis that miRNA profiles in CD8$^+$ T cells from adult and neonatal mice were surprisingly similar during infection, but infection miRNA levels differed when it was absent. In particular, marked differences were observed in the miR-29 and miR-130 expression levels between adult and neonatal cells before infection. Likewise, changes in the expression of messenger RNA targets have been noted for both miR-29 and miR-130 [48].

Our study indicated a difference in the miR-23b expression levels in both EOS and LOS. The miR-23b expression levels increased in the EOS patients with a positive haemoculture and lowered in the LOS patients with either premature or full-term newborns. Nevertheless, we also observed a difference in expression over time in the control group before and after 72 h of birth. This could be due to differences in the genome expression patterns in newborns between EOS and LOS. Exclusively to newborns, uninfected status and host response to sepsis are significantly affected by time of birth [49, 50], in which immune system development is a continuous process throughout embryogenesis and into childhood. Hence the different miRNAs expression in neonatal sepsis could be considered a developmental characteristic of the immune response [40]. Early and late sepsis responses considerably differ depending on the postnatal age at the time of sepsis [51]. By controlling postnatal age in studies on epigenetic changes during neonatal sepsis, we were able to better understand the immune mechanism in newborns and to identify therapeutic targets. From these results, we suggest the possibility of using miR-23b levels as an in vitro diagnosis marker, which can be used to differentiate between EOS and LOS. miR-23b levels are up-regulated during the first 72 h of life and down-regulated over time during this period.

**Conclusions**

In this first report, we demonstrate the usefulness of miRNAs in haemocultures from neonates, and the role of miR-23b as a potent biomarker in sepsis. This study could be of much interest in not only research, but also in Translational Medicine, and more specifically in Neonatal Infectiology, where the use of large volumes of blood is not possible. In fine, this study provides additional elements into the molecular approach for diagnosing and treating neonatal sepsis. These elements include three essential points: (i) miR-23b plays a vital role in neonatal sepsis; (ii) the expression of miR-23b differs during the neonatal period; (iii) miR-23b expression levels are up-regulated in EOS and down-regulated in LOS.

**Abbreviations**
BPM: beats per minute
BrPM: breaths per minute
CF: Cardiac frequency
Co/NH: control newborns with negative haemoculture
CRP: C-reactive protein
DP/NH: patients who died with negative haemoculture
DP/PH: patients who died with positive haemoculture
EOS: early-onset sepsis
F: female
Gly: glycaemia
HR: Heart rate
KW: Kruskal-Wallis
LOS: late-onset sepsis
LPS: lipopolysaccharide
M: male
miRNAs: MicroRNAs
NH: negative haemoculture
NS: not significant
PBMCs: peripheral blood mononuclear cells
PROM: premature rupture of membranes
PD-L1: programmed death ligand-1
RR: Respiratory rate
SP/PH: patients who survived with positive haemoculture
VD vs. CD: vaginal vs. caesarean delivery
Declarations

- Ethical Approval and Consent to participate

The present study was approved by the Local Ethics Committee of Tlemcen University. Parents or legal guardians gave written informed consent so that the samples from all the participating infants could be used according to the Declaration of Helsinki.

  - Consent for publication

All authors give the consent for publication

  - Availability of supporting data

No applicable

  - Competing interests

The authors declare no conflict of interest.

  - Funding

Saving Lives at Birth consortium Project number: 0456-03_40

  - Authors’ contributions

AF: performed experiments, statistical analyses and drafted the manuscript. SAR: provided advice and participated in refreshing references. HZ: participated in microbial identification. HZ and YE: performed experiments. NC: financial support, study design and advice. SB: recruited eligible patients, traceability of samples and consents. JSIC performed experiments, JLGG: study design and interpretation of the results. MA: coordinated the study, interpretation of the results and proofread the manuscript. FVP: study design, interpretation of the results, financial support and proofread the manuscript.

  - Acknowledgements

We appreciate the participation of the families and all the critical care doctors and nurses of the Neonatal Department of Specialized Maternal & Child Hospital of Tlemcen. We would also thank Grand Challenges Canada and the “Saving Lives at Birth” consortium.

References

1. Kumar SKM, Bhat BV (2016) Distinct mechanisms of the newborn innate immunity. Immunol Lett 173:42–54. https://doi.org/10.1016/j.imlet.2016.03.009
2. Lucignano B, Ranno S, Liesenfeld O, et al (2011) Multiplex PCR Allows Rapid and Accurate Diagnosis of Bloodstream Infections in Newborns and Children with Suspected Sepsis. J Clin Microbiol 49:2252–2258. https://doi.org/10.1128/JCM.02460-10

3. Bhandari V (2014) Effective Biomarkers for Diagnosis of Neonatal Sepsis. J Pediatr Infect Dis Soc 3:234–245. https://doi.org/10.1093/jpids/piu063

4. Panwar C, Kaushik S, Kaushik R, Sood A (2017) Correlation of neonatal and maternal clinico-hematological parameters as predictors of early onset neonatal sepsis. Int J Contemp Pediatr. https://doi.org/10.18203/2349-3291.ijcp20164516

5. Ansari S, Nepal HP, Gautam R, et al (2015) Neonatal Septicemia in Nepal: Early-Onset versus Late-Onset. Int J Pediatr 2015:1–6. https://doi.org/10.1155/2015/379806

6. Cortese F, Scicchitano P, Gesualdo M, et al (2016) Early and Late Infections in Newborns: Where Do We Stand? A Review. Pediatr Neonatol 57:265–273. https://doi.org/10.1016/j.pedneo.2015.09.007

7. Ng PC (2004) Diagnostic markers of infection in neonates. Arch Dis Child Fetal Neonatal Ed 89:F229-235

8. Shane AL, Sánchez PJ, Stoll BJ (2017) Neonatal sepsis. The Lancet 390:1770–1780. https://doi.org/10.1016/S0140-6736(17)31002-4

9. Atif ML, Sadaoui F, Bezzaoucha A, et al (2008) Prolongation of Hospital Stay and Additional Costs Due to Nosocomial Bloodstream Infection in an Algerian Neonatal Care Unit. Infect Control Hosp Epidemiol 29:1066–1070. https://doi.org/10.1086/591858

10. Wagstaff JS, Durrant RJ, Newman MG, et al (2019) Antibiotic Treatment of Suspected and Confirmed Neonatal Sepsis Within 28 Days of Birth: A Retrospective Analysis. Front Pharmacol 10:1191. https://doi.org/10.3389/fphar.2019.01191

11. Wu M, Gu J-T, Yi B, et al (2015) microRNA-23b regulates the expression of inflammatory factors in vascular endothelial cells during sepsis. Exp Ther Med 9:1125–1132. https://doi.org/10.3892/etm.2015.2224

12. Lenkala D, LaCroix B, Gamazon ER, et al (2014) The impact of microRNA expression on cellular proliferation. Hum Genet 133:931–938. https://doi.org/10.1007/s00439-014-1434-4

13. Wang J, Yu M, Yu G, et al (2010) Serum miR-146a and miR-223 as potential new biomarkers for sepsis. Biochem Biophys Res Commun 394:184–188. https://doi.org/10.1016/j.bbrc.2010.02.145

14. Wang W, Wang Y, Liu W, van Wijnen AJ (2018) Regulation and biological roles of the multifaceted miRNA-23b (MIR23B). Gene 642:103–109. https://doi.org/10.1016/j.gene.2017.10.085

15. Zhu S, Pan W, Song X, et al (2012) The microRNA miR-23b suppresses IL-17-associated autoimmune inflammation by targeting TAB2, TAB3 and IKK-α. Nat Med 18:1077–1086. https://doi.org/10.1038/nm.2815

16. Ou H, Xiao X, Jiang Y, et al (2018) Expression of microRNA-23b in patients with sepsis and its effect on leukocytes and the expression of E-selectin and ICAM-1. Exp Ther Med. https://doi.org/10.3892/etm.2018.6759
17. Zhang H, Caudle Y, Shaikh A, et al (2018) Inhibition of microRNA-23b prevents polymicrobial sepsis-induced cardiac dysfunction by modulating TGIF1 and PTEN. Biomed Pharmacother 103:869–878. https://doi.org/10.1016/j.biopha.2018.04.092

18. Beltrán-García J, Osca-Verdegal R, Romá-Mateo C, et al (2020) Epigenetic biomarkers for human sepsis and septic shock: insights from immunosuppression. Epigenomics epi-2019-0329. https://doi.org/10.2217/epi-2019-0329

19. Zhang W, Lu F, Xie Y, et al (2019) miR-23b Negatively Regulates Sepsis-Induced Inflammatory Responses by Targeting ADAM10 in Human THP-1 Monocytes. Mediators Inflamm 2019:1–13. https://doi.org/10.1155/2019/5306541

20. Tsalik EL, Jones D, Nicholson B, et al (2010) Multiplex PCR To Diagnose Bloodstream Infections in Patients Admitted from the Emergency Department with Sepsis. J Clin Microbiol 48:26–33. https://doi.org/10.1128/JCM.01447-09

21. Gurtler V, Stanisich VA (1996) New approaches to typing and identification of bacteria using the 16S-23S rDNA spacer region. Microbiology 142:3–16. https://doi.org/10.1099/13500872-142-1-3

22. Draz NI, Taha SE, Abou Shady NM, Abdel Ghany YS (2013) Comparison of broad range 16S rDNA PCR to conventional blood culture for diagnosis of sepsis in the newborn. Egypt J Med Hum Genet 14:403–411. https://doi.org/10.1016/j.ejmhg.2013.05.004

23. Singer M, Deutschman CS, Seymour CW, et al (2016) The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 315:801. https://doi.org/10.1001/jama.2016.0287

24. Olsen CH (2003) Review of the use of statistics in infection and immunity. Infect Immun 71:6689–6692. https://doi.org/10.1128/iai.71.12.6689-6692.2003

25. Hall KK, Lyman JA (2006) Updated Review of Blood Culture Contamination. Clin Microbiol Rev 19:788–802. https://doi.org/10.1128/CMR.00062-05

26. Jordana-Lluch E, Giménez M, Quesada MD, et al (2014) Improving the Diagnosis of Bloodstream Infections: PCR Coupled with Mass Spectrometry. BioMed Res Int 2014:1–8. https://doi.org/10.1155/2014/501214

27. Say L, Souza JP, Pattinson RC (2009) Maternal near miss – towards a standard tool for monitoring quality of maternal health care. Best Pract Res Clin Obstet Gynaecol 23:287–296. https://doi.org/10.1016/j.bpobgyn.2009.01.007

28. Gonzalez RM, Gilleskie D (2017) Infant Mortality Rate as a Measure of a Country’s Health: A Robust Method to Improve Reliability and Comparability. Demography 54:701–720. https://doi.org/10.1007/s13524-017-0553-7

29. Nedeva C, Menassa J, Puthalakath H (2019) Sepsis: Inflammation Is a Necessary Evil. Front Cell Dev Biol 7:108. https://doi.org/10.3389/fcell.2019.00108

30. Kollmann TR, Levy O, Montgomery RR, Goriely S (2012) Innate Immune Function by Toll-like Receptors: Distinct Responses in Newborns and the Elderly. Immunity 37:771–783. https://doi.org/10.1016/j.immuni.2012.10.014

31. Bartel DP (2004) MicroRNAs. Cell 116:281–297. https://doi.org/10.1016/S0092-8674(04)0045-5
32. Yu H-R, Huang L-H, Li S-C (2018) Roles of microRNA in the immature immune system of neonates. Cancer Lett 433:99–106. https://doi.org/10.1016/j.canlet.2018.06.014
33. Li YC, Chen Y, Liu W, Thadhani R (2014) MicroRNA-mediated mechanism of vitamin D regulation of innate immune response. J Steroid Biochem Mol Biol 144:81–86. https://doi.org/10.1016/j.jsbmb.2013.09.014
34. Chen C-Z, Schaffert S, Fragoso R, Loh C (2013) Regulation of immune responses and tolerance: the microRNA perspective. Immunol Rev 253:112–128. https://doi.org/10.1111/imr.12060
35. Kingsley Manoj Kumar S, Vishnu Bhat B (2015) Current challenges and future perspectives in neonatal sepsis. Pediatr Infect Dis 7:41–46. https://doi.org/10.1016/j.pid.2015.10.005
36. Wang H, Zhang P, Chen W, et al (2013) Characterization and Identification of Novel Serum MicroRNAs in Sepsis Patients With Different Outcomes: Shock 39:480–487. https://doi.org/10.1097/SHK.0b013e3182940cb8
37. Wang H, Zhang P, Chen W, et al (2012) Four serum microRNAs identified as diagnostic biomarkers of sepsis: J Trauma Acute Care Surg 73:850–854. https://doi.org/10.1097/TA.0b013e31825a7560
38. Stearns-Kurosawa DJ, Osuchowski MF, Valentine C, et al (2011) The Pathogenesis of Sepsis. Annu Rev Pathol Mech Dis 6:19–48. https://doi.org/10.1146/annurev-pathol-011110-130327
39. Zhang W, Jia J, Liu Z, et al (2019) Circulating microRNAs as biomarkers for Sepsis secondary to pneumonia diagnosed via Sepsis 3.0. BMC Pulm Med 19:93. https://doi.org/10.1186/s12890-019-0836-4
40. Chen J, Jiang S, Cao Y, Yang Y (2014) Altered miRNAs Expression Profiles and Modulation of Immune Response Genes and Proteins During Neonatal Sepsis. J Clin Immunol 34:340–348. https://doi.org/10.1007/s10875-014-0004-9
41. Sweeney TE, Wynn JL, Cernada M, et al (2018) Validation of the Sepsis MetaScore for Diagnosis of Neonatal Sepsis. J Pediatr Infect Dis Soc 7:129–135. https://doi.org/10.1093/jpids/pix021
42. Cheng Q, Tang L, Wang Y (2018) Regulatory role of miRNA-26a in neonatal sepsis. Exp Ther Med. https://doi.org/10.3892/etm.2018.6779
43. Wang X, Wang X, Liu X, et al (2015) miR-15a/16 are upregulated in the serum of neonatal sepsis patients and inhibit the LPS-induced inflammatory pathway. Int J Clin Exp Med 8:5683–5690
44. Bordon Y (2012) MicroRNA-23b keeps TABs on tissue inflammation. Nat Rev Immunol 12:475–475. https://doi.org/10.1038/nri3250
45. Grossi I, Salvi A, Baiocchi G, et al (2018) Functional Role of microRNA-23b-3p in Cancer Biology. MicroRNA 7:156–166. https://doi.org/10.2174/2211536607666180629155025
46. Zhao B, Li H, Liu J, et al (2016) MicroRNA-23b Targets Ras GTPase-Activating Protein SH3 Domain-Binding Protein 2 to Alleviate Fibrosis and Albuminuria in Diabetic Nephropathy. J Am Soc Nephrol 27:2597–2608. https://doi.org/10.1681/ASN.2015030300
47. Pimenta RC, Viana NI, Amaral GQ, et al (2018) MicroRNA-23b and microRNA-27b plus flutamide treatment enhances apoptosis rate and decreases CCNG1 expression in a castration-resistant
prostate cancer cell line. Tumor Biol 40:1010428318803011. https://doi.org/10.1177/1010428318803011
48. Wissink EM, Smith NL, Spektor R, et al (2015) MicroRNAs and Their Targets Are Differentially Regulated in Adult and Neonatal Mouse CD8+ T Cells. Genetics 201:1017–1030. https://doi.org/10.1534/genetics.115.179176
49. Wynn JL, Guthrie SO, Wong HR, et al (2015) Postnatal Age Is a Critical Determinant of the Neonatal Host Response to Sepsis. Mol Med 21:496–504. https://doi.org/10.2119/molmed.2015.00064
50. Raymond SL, Stortz JA, Mira JC, et al (2017) Immunological Defects in Neonatal Sepsis and Potential Therapeutic Approaches. Front Pediatr 5:. https://doi.org/10.3389/fped.2017.00014
51. Ng S, Strunk T, Jiang P, et al (2018) Precision Medicine for Neonatal Sepsis. Front Mol Biosci 5:70. https://doi.org/10.3389/fmolb.2018.00070

Table

Table 1. Characteristics of the newborn patients with sepsis in the present study
|                     | Full-term patients |                     | Premature patients |   |
|---------------------|--------------------|-------------------|-------------------|---|
| EOS/LOS             | Co/NH (control)    | SP/PH             | DP/PH             | Co/NH (control) | SP/PH | DP/PH |
| (n = 27, 21)        | (9, 6)             | (7, 12)           | (2, 1)            | (4, 0)          | (2)   | (0)   |
| Gender (M/F)        | EOS 5/4            | 4/3               | 1/1               | 1/3             | 1/1   | 2/1   |
|                     | LOS 6/0            | 6/6               | 0/1               | 2/0             | -     | -     |
| Weight (kg)         | EOS 2.87 ± 0.76    | 3.16 ± 0.65       | 3.30 ± 0.14       | 2.01 ± 0.09     | 1.43 ± 0.23 | 1.63 ± 0.57 | <0.001 |
|                     | LOS 3.17 ± 0.86    | 3 ± 0.86          | 2.5 ± 0.28        | -               | -     | -     | <0.001 |
| T (°C)              | EOS 36.17 ± 1.43   | 35.05 ± 1.42      | 34.5 ± 1.27       | 36.35 ± 2.30    | 33.07 ± 2.21  | 36.17 ± 1.20 | NS   |
|                     | LOS 37.33 ± 2.85   | 38.3 ± 1.53       | 37.4 ± 0.95       | -               | -     | -     | NS   |
| HR (BPM)            | EOS 136 ± 16.37    | 143.6 ± 17.87     | 125 ± 9.9         | 120.5 ± 19.58   | 125 ± 7.07    | 150 ± 10 | NS   |
|                     | LOS 151.8 ± 27     | 140.3 ± 17.27     | 180 ± 0           | 135 ± 7.07      | -     | -     | NS   |
| RR (BrPM)           | EOS 55.3 ± 14.56   | 55.7 ± 17.1       | 38 ± 5.66         | 58 ± 5.42       | 42 ± 2.83 | 62.67 ± 4.72 | NS   |
|                     | LOS 50.7 ± 14.01   | 52.5 ± 6.1        | 52 ± 0            | 42 ± 2.83       | -     | -     | NS   |
| Gly (mg/dL)         | EOS 0.95 ± 0.48    | 0.63 ± 0.23       | 0.52 ± 0.60       | 0.73 ± 0.25     | -     | 0.45 ± 0.15 | NS   |
|                     | LOS 1.12 ± 0.22    | 0.65 ± 0.21       | -                 | 0.66 ± 0.17     | -     | -     | NS   |
| CRP (mg/dL)         | EOS 25.78 ± 17.87  | 41.17 ± 30.75     | -                 | 63 ± 88.25      | -     | -     | <0.0001 |
|                     | LOS 47 ± 81.37     | 39.87 ± 29.78     | -                 | 42 ± 25.45      | -     | -     | NS   |
| VD vs. CD           | EOS 5/4            | 5/2               | 1/1               | 2/2             | 1/1   | 1/2   | NS   |
|                     | LOS 5/1            | 1/1               | 1/0               | 2/0             | -     | -     | NS   |

Data are presented as the mean ± standard deviation (X ± SD). BPM: beats per minute, BrPM: breaths per minute, CF: Cardiac frequency, Co/ NH: control newborns with negative haemoculture, CRP: C-reactive protein, DP/NH: patients who died with negative
haemoculture, DP/PH: patients who died with positive haemoculture, EOS: early onset sepsis, F: female, Gly: glycaemia, HR: Heart rate, EOS: early onset sepsis, LOS: late onset sepsis, M: male, NS: not significant, RR: Respiratory rate, SP/PH: patients who survived with positive haemoculture, VD vs. CD: vaginal vs. caesarean delivery.

Figures

Figure 1

Scatter plot values represent the miR-23b level for EOS in the at-term newborns, reported as (2-ΔΔCT). The boxplots in b on the right represent the miR-23b level in the premature newborns. The line inside the boxes corresponds to the median values, and the top and bottom of boxes represent the 75th and 25th percentiles. For the at-term patients, Co/NH (n=9), DP/PH (n=2), SP/PH (n=7). For the premature patients, Co/NH (n=4), DP/PH (n=3), SP/PH (n=2). Co/NH: negative haemoculture, DP/PH: positive haemoculture in dead newborns, SP/PH: positive haemoculture in the newborns who survived. KW: Kruskal-Wallis. The asterisks indicate significant differences between the peer review: Black stars indicate significant differences between the groups of patients with positive haemoculture and negative haemoculture: *p < 0.05, **p < 0.005, ***p < 0.001, ****p < 0.0001. The sharp indicate significant differences highlighted between all groups using the Kruskal-Wallis test: p <0.001
Figure 2

Scatter plot values represent the miR-23b level for LOS in the premature and at-term newborns reported as (2-ΔΔCT). The line inside the boxes corresponds to the median values, and the top and bottom of boxes represent the 75th and 25th percentiles. Co/NH (n=6), DP/NH (n=2), SP/PH (n=12), DP/PH (n=1). Co/NH: negative haemoculture, DP/NH: negative haemoculture in the dead newborns, DP/PH: positive haemoculture in the newborns who died, SP/PH: positive haemoculture in the newborns who survived, KW: Kruskal-Wallis. The asterisks indicate significant differences between the peer review: Black stars indicate significant differences between the groups of patients with positive haemoculture and negative haemoculture: *p < 0.05, **p < 0.005. The sharp indicate significant differences highlighted between all groups using the Kruskal-Wallis test: p < 0.005
Figure 3

Scatter plot values represent the miR-23b level for the negative control of EOS (n=9) and the negative control of LOS (n=6) in terms of the newborns reported as (2-ΔΔCT). The line inside the boxes corresponds to the median values, and the top and bottom of boxed represent the 75th and 25th percentiles. LOS/ Bac-: negative haemoculture in LOS, Co/NH before 72 h: negative haemoculture in EOS, where patients’ age was less than 72 h, Co/NH / before 72 h: negative haemoculture in LOS, where patients’ age was more than 72 h. *p = 0.011 via the Mann-Whitney U test
Figure 4

(a) miRNA-23b (2^ΔΔct) with a correlation coefficient of $r = -0.96$.

(b) miRNA-23b (2^ΔΔct) with a correlation coefficient of $r = -0.89$.

(c) miRNA-23b (2^ΔΔct) comparison among different groups.
Individual values represent the correlation with the miR-23b level, survivor and dead in newborns with sepsis. a: in early onset sepsis in at-term newborns, b: early onset sepsis in premature newborns, c: late onset sepsis in at-term newborns. Control: patients with negative haemoculture, dead: dead patients with sepsis, survivor: survivor patients with sepsis, r: correlation coefficient.